Darolutamide (Nubeqa) for Prostate Cancer
Date: December 16, 2019
Issue #:
1587Summary:
The FDA has approved darolutamide (Nubeqa–
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide(Erleada) and enzalutamide(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: apalutamide darolutamide enzalutamide Erleada Nubeqa Prostate cancer Xtandi Source Type: research